MSM:Will work for compounds

MSM Protein Technologies Inc. believes its Magnetic Proteo-Liposome technology may provide an advantage over other display and screening technologies in that it is able to display transmembrane proteins in their native, functional form. The company is using the technology to screen its partners' libraries and hopes to use these deals to get access to compounds for its own pipeline.

According to Chairman Davis Farmer, transmembrane proteins such as GPCRs, ion channels and transporters account for more than 50% of therapeutic targets. However, when proteins are removed from the endogenous cell, they can no longer be used as screening targets since they lose their functional form and, along with it, their native binding properties...